GENMAB A/SGMABEarnings & Financial Report
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
GMAB Q2 FY2025 Key Financial Metrics
Revenue
$925.0M
Gross Profit
$868.0M
Operating Profit
$360.0M
Net Profit
$336.0M
Gross Margin
93.8%
Operating Margin
38.9%
Net Margin
36.3%
YoY Growth
18.7%
EPS
$5.42
GENMAB A/S Q2 FY2025 Financial Summary
GENMAB A/S reported revenue of $925.0M (up 18.7% YoY) for Q2 FY2025, with a net profit of $336.0M (up 65.5% YoY) (36.3% margin). Cost of goods sold was $57.0M, operating expenses totaled $508.0M.
Key Financial Metrics
| Total Revenue | $925.0M |
|---|---|
| Net Profit | $336.0M |
| Gross Margin | 93.8% |
| Operating Margin | 38.9% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
GENMAB A/S Q2 FY2025 revenue of $925.0M breaks down across 9 segments, led by Darzalex at $638.0M (69.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Darzalex | $638.0M | 69.0% |
| Kesimpta | $108.0M | 11.7% |
| Net Product Sales | $101.0M | 10.9% |
| Other | $28.0M | 3.0% |
| Tepezza | $20.0M | 2.2% |
| Reimbursement Revenue | $13.0M | 1.4% |
| Bio N Tech | $11.0M | 1.2% |
| Abb Vie | $5.0M | 0.5% |
| Milestone Revenue | $1.0M | 0.1% |
GENMAB A/S Quarterly Revenue & Net Profit History
GENMAB A/S results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $925.0M | +18.7% | $336.0M | 36.3% |
| Q2 FY2024 | $779.0M | +28.9% | $203.0M | 26.1% |
| Q2 FY2023 | $604.5M | +31.8% | $193.6M | 32.0% |
| Q2 FY2022 | $458.5M | +60.3% | $274.2M | 59.8% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $458.5M | $604.5M | $779.0M | $925.0M |
| YoY Growth | 60.3% | 31.8% | 28.9% | 18.7% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $3.98B | $4.64B | $5.60B | $6.46B |
| Liabilities | $434.1M | $467.3M | $1.11B | $1.16B |
| Equity | $3.55B | $4.14B | $4.45B | $5.30B |
Cash Flow
| Q2 2024 | Q2 2025 | |
|---|---|---|
| Operating CF | $438.0M | $349.0M |